China NMPA Drug Inspection - Harbin Pharmaceutical Group Biotechnology Co., Ltd. - Paclitaxel Injection
China NMPA drug inspection for Harbin Pharmaceutical Group Biotechnology Co., Ltd. published May 10, 2019. Drug: Paclitaxel Injection. The National Medical Products Administration (NMPA) released an announcement on May 8, 2019, detailing significant quali
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Harbin Pharmaceutical Group Biotechnology Co., Ltd. published May 10, 2019. Drug: Paclitaxel Injection. The National Medical Products Administration (NMPA) released an announcement on May 8, 2019, detailing significant quali
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox